Clinical Trials - May 9, 2016
Nordic Nanovector announces an open Investigational New Drug application
Nordic Nanovector announces that its Investigational New Drug (IND) application for a new Phase 1 clinical study of Betalutin in a second non-Hodgkin lymphoma (NHL) indication is now open with the US Food & Drug Administration (FDA). The Company plans to investigate Betalutin in relapsed diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for […]
Clinical Trials - May 6, 2016
Nordic Nanovector enrols first patient in extended Betalutin study
Nordic Nanovector announces that the first patient has been enrolled into one of the two new arms of its expanded Lymrit 37-01 clinical study with Betalutin. Betalutin is a novel anti-CD37 targeting Antibody Radionuclide Conjugate in development for the treatment of major types of non-Hodgkin’s lymphoma (NHL), including Follicular Lymphoma (FL). The new arm (Arm 3) […]
Clinical Trials - April 18, 2016
Nordic Nanovector’s Betalutin shows promise
Nordic Nanovector’s Betalutin continues to show promising efficacy and increasing Duration of Response. Nordic Nanovector, a biotechnology company focusing on the development of novel targeted therapeutics in haematology and oncology, announces updated results of its ongoing Phase 1/2 study with Betalutin in relapsed non-Hodgkin lymphoma (NHL) patients. Betalutin was generally well tolerated and showed a […]
Collaboration - April 11, 2016
Nordic Nanovector collaborates with Paul Scherrer Institute
Nordic Nanovector has entered into a research and development collaboration programme with Paul Scherrer Institute (PSI) in Switzerland. The collaboration aims at developing new antibody radionuclide conjugates (ARCs) optimised for the treatment of single cell leukaemias, such as chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). CLL and AML are serious orphan diseases with […]
Business Award - February 1, 2016
Nordic Nanovector awarded NOK 15 million
Nordic Nanovector has announced the award of a up to NOK 15 million grant from the Research Council of Norway’s User-driven Research-based Innovation programme to support the research and development of novel targeted therapeutics for leukemia and non-Hodgkin Lymphoma. The award is based on the promising potential for value creation, both for patients and the society […]
Acquisition - March 24, 2015
Skavak Buys Nordic Nanovector Shares
Skavak Invest AS, a company controlled by a close associate of Tone Kvåle, who is the chief financial officer of Nordic Nanovector ASA, purchased 3,000 shares in Nordic Nanovector ASA at an average share price of NOK 35 per share. Following the transaction and completion of the offering, Tone Kvåle will own 38,292 shares and […]
